Patritumab deruxtecan

• CAT Number: I041541
• CAS Number: 2227102-46-5
• Purity: ≥95%

Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1].
Patritumab deruxtecan exhibits activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression[1].
Patritumab deruxtecan (0-100 nM) binds to the surface of all HER3-mutant and HER3WT MDA-MB-231 cells in a concentration-dependent manner, but does not bind to the surface of HER3EV cells[1].

Reference

[1]. Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027.
 [Content Brief]